iCarbonX, the Shenzhen big data/artificial intelligence health company, formed The Digital Life Alliance with seven outside life science companies, complete with a total investment of nearly $400 million from the iCarbonX ecosystem; Ascletis of Hangzhou completed a $100 million series B financing to build a sales force and acquire additional liver disease drugs; Nanjing Frontier Biotech, which is developing a novel AIDS treatment, raised $43 million in a Series C round; MabSpace of Suzhou will collaborate with San Diego’s Ambrx to discover multiple novel antibody drug conjugates; Lee’s Pharm in-licensed China rights to a clinic-ready treatment for wet age-related macular degeneration from TOT Biopharma of Suzhou; BIT Group of Germany officially opened EMD Shenzhen, a Joint Venture with EDAN Instruments that offers CMO services for IVD products; Taiwan’s TLC reported positive top-line results from the Phase I/II trial of TLC599, a sustained release corticosteroid; and Beijing’s Yisheng Biopharma was granted US Orphan Drug designation for a novel PIKA rabies vaccine.
